Dr. John Cush RheumNow
3 years 7 months ago
Meta-analysis (21 studies, 3948 pregnant pts) HCQ may reduce risk of preeclampsia (OR 0.45) & premature delivery (OR 0.84) in pregnant autoimmune pts. HCQ may also reduce risk of gestational HTN (OR 0.42) & pre-term birth (OR 0.63) in pregnant SLE pts https://t.co/riQDRN9r1A https://t.co/uR8Nem4Ndx
Dr. John Cush RheumNow
3 years 7 months ago
Benlysta granted Orphan Drug Designation by US FDA as potential Rx of systemic sclerosis, such status facilitates eval in rare diseases. GSK is planning a trial of belimumab for SSc-associated interstitial lung disease in the first half of 2023 https://t.co/kWItB7NEvn https://t.co/eVbQtKy98H
Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on RheumNow.com.
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://bit.ly/3DSNMmL
Dr. John Cush RheumNow
3 years 7 months ago
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://t.co/KTYn1kv3qO https://t.co/eWbvMSBLxm
Dr. John Cush RheumNow
3 years 7 months ago
211 Adult Crohn's pts w/ steroid-free remission >6mo on Combo infliximab & immunosuppressant either cont combo or W/D IFX or Immsup. 2-yr relapse rates: 14% Combo vs, 36% IFX vs 10% Immunosup. WD of IFX had 3.45-4.76 fold incr rsk of flare https://t.co/6EbM3Vx0Ei https://t.co/5ZOE2oxCl0
Dr. John Cush RheumNow
3 years 7 months ago
Did you have a chance to listen to last week's RheumNow podcast? Dr. Cush covers rheumatology news from the last week. Make sure to tune in before we release our next episode tomorrow!
https://t.co/uRRg2K2K1a https://t.co/MjWF3Zl05i
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.
Dr. John Cush RheumNow
3 years 7 months ago
Treatment failures studied in 718 RA pts
- csDMARDs D/Cs intolerance (22%), inefficacy (20%), acute Rxns (5%), severe infx(0.6%)
- bDMARDs D/Cs inefficacy (29%), intolerance (10%), acute Rxns (6%), severe infx (1.5%)
- Multi-drug ifailure 5.7-8.4% https://t.co/FdoP77uELe https://t.co/dQjTNncABc
Dr. John Cush RheumNow
3 years 7 months ago
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/PjTQNHhduB https://t.co/m0erNXMkUC
Dr. John Cush RheumNow
3 years 7 months ago
GRAPPA Recommendations for Treating Enthesitis in PsA
GRAPPA has provided new updates to the mgmt of enthesitis in patients with PsA, affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
https://t.co/AC6KHGMeo0
Dr. John Cush RheumNow
3 years 7 months ago
New 5 Peptide Autoantibody Panel Complements RA Diagnosis
Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.
https://t.co/twgULvokPY https://t.co/O0I4i81RAN
Dr. John Cush RheumNow
3 years 7 months ago
Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3 with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, and calcinosis (but not renal crisis, ILD, or pulmonary HTN
https://t.co/Usrfr0XcCJ https://t.co/pmwkHsaJOx
There are several reports suggesting a link between methotrexate (MTX) use and certain skin cancers, yet these are confounded by a higher risk of skin cancers with inflammatory conditions like rheumatoid arthritis of which MTX is the most common treatment.
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active systemic lupus erythematosus (SLE).
